A Phase 3 interventional study of adalimumab 40 mg and sirukumab 100 mg in Arthritis, Rheumatoid, sponsored by Janssen Research & Development, LLC. Completed at 109 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-26.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 4 that started in 2014, is one of 36 in phase 3, and was the 56th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 559 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
90 studies in Arthritis, Rheumatoid by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 86 finished, 31 (36%) have results posted.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 11th largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2014, is one of 20 in phase 3, and was the 75th registered.
Johnson & Johnson’s Arthritis, Rheumatoid studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 90 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.
This is a randomized, double-blind, parallel-group, global, multicenter study of subcutaneous (SC) sirukumab monotherapy compared with adalimumab monotherapy in subjects with active rheumatoid arthritis. Approximately 510 subjects will be randomly assigned in a 1:1:1 ratio to receive treatment with adalimumab 40 mg SC every 2 weeks, sirukumab 100 mg SC every 2 weeks, or 50 mg SC every 4 weeks, with approximately 170 subjects per treatment group. At Week 16, subjects in all treatment groups who have \< 20% improvement from baseline in both swollen and tender joint counts will qualify for early escape. The expected duration of the study is 68 weeks. This includes 52 weeks of treatment with study agent and 16 weeks of safety follow-up after the last study agent administration. The study will end when the last subject completes the last scheduled visit (Week 68 visit or completes the 16 week safety follow-up, whichever is later). Subject safety will be monitored through the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
Biological: adalimumab 40 mg
Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (\< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
Biological: sirukumab 100 mg · Drug: Placebo
Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
Biological: sirukumab 50 mg · Drug: Placebo
SC injections
Also known as: HUMIRA®
SC injections
Also known as: CNTO 136
SC injections
Also known as: CNTO 136
SC injections
Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24
The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).
Time frame: Baseline and Week 24
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24
The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, \[0=no arthritis activity to 10=extremely active arthritis\]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
Time frame: Week 24
Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24
The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst). The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.
Time frame: Week 24
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24
The ACR 20 Response is defined as \>= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.
Time frame: Week 24
| Milestone | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|
| Started | 186 | 186 | 187 |
| Completed | 149 | 134 | 145 |
| Not completed | 37 | 52 | 42 |
| Withdrew: Adverse event | 14 | 23 | 17 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 7 | 4 | 4 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Physician decision | 1 | 2 | 0 |
| Withdrew: Pregnancy | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 11 | 10 | 11 |
| Withdrew: Other | 3 | 8 | 6 |
The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).
| units on a scale | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|
| Baseline | 6.89 ± 0.851 | 6.90 ± 0.881 | 6.91 ± 0.863 |
| Change from Baseline at Week 24 | -2.19 ± 1.437 | -2.58 ± 1.524 | -2.96 ± 1.58 |
The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, \[0=no arthritis activity to 10=extremely active arthritis\]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
| Percentage of participants | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24 | 31.7 | 26.9 | 35.3 |
The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst). The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.
| Percentage of participants | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|
| Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24 | 7.5 | 12.9 | 20.3 |
The ACR 20 Response is defined as \>= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.
| Percentage of participants | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 | 56.5 | 53.8 | 58.8 |
Collected over Screening, up to Week 68. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg q2w Only | — | 15/173 (8.7%) | 71/173 (41%) |
| Adalimumab 40 mg q2w Then 40 mg q1w | — | 1/13 (7.7%) | 3/13 (23.1%) |
| Adalimumab 40 mg | — | 16/186 (8.6%) | 74/186 (39.8%) |
| Sirukumab 50 mg q4w Only | — | 23/160 (14.4%) | 79/160 (49.4%) |
| Sirukumab 50 mg q4w Then 100 mg q2w | — | 6/26 (23.1%) | 13/26 (50%) |
| Sirukumab 50 mg | — | 29/186 (15.6%) | 92/186 (49.5%) |
| Sirukumab 100 mg | — | 22/187 (11.8%) | 86/187 (46%) |
| Event | Adalimumab 40 mg q2w Only | Adalimumab 40 mg q2w Then 40 mg q1w | Adalimumab 40 mg | Sirukumab 50 mg q4w Only | Sirukumab 50 mg q4w Then 100 mg q2w | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|---|---|---|---|
| Sinus node dysfunctionCardiac disorders | 0/173 | 1/13 | 1/186 | 0/160 | 0/26 | 0/186 | 0/187 |
| Coronary artery diseaseCardiac disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| Diverticular perforationGastrointestinal disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| ErysipelasInfections and infestations | 1/173 | 0/13 | 1/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| SynovitisMusculoskeletal and connective tissue disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| Gliomatosis cerebriNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/173 | 0/13 | 0/186 | 0/160 | 1/26 | 1/186 | 0/187 |
| Atrial fibrillationCardiac disorders | 1/173 | 0/13 | 1/186 | 2/160 | 0/26 | 2/186 | 0/187 |
| Event | Adalimumab 40 mg q2w Only | Adalimumab 40 mg q2w Then 40 mg q1w | Adalimumab 40 mg | Sirukumab 50 mg q4w Only | Sirukumab 50 mg q4w Then 100 mg q2w | Sirukumab 50 mg | Sirukumab 100 mg |
|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 13/173 | 0/13 | 13/186 | 15/160 | 2/26 | 17/186 | 33/187 |
| Aspartate aminotransferase increasedInvestigations | 11/173 | 0/13 | 11/186 | 9/160 | 4/26 | 13/186 | 20/187 |
| HeadacheNervous system disorders | 9/173 | 2/13 | 11/186 | 10/160 | 1/26 | 11/186 | 13/187 |
| HypertensionVascular disorders | 9/173 | 1/13 | 10/186 | 8/160 | 4/26 | 12/186 | 8/187 |
| Alanine aminotransferase increasedInvestigations | 12/173 | 0/13 | 12/186 | 18/160 | 3/26 | 21/186 | 24/187 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 17/173 | 0/13 | 17/186 | 17/160 | 3/26 | 20/186 | 15/187 |
| NeutropeniaBlood and lymphatic system disorders | 4/173 | 0/13 | 4/186 | 16/160 | 1/26 | 17/186 | 11/187 |
| NasopharyngitisInfections and infestations | 16/173 | 0/13 | 16/186 | 9/160 | 1/26 | 10/186 | 9/187 |
| Injection site pruritusGeneral disorders | 8/173 | 0/13 | 8/186 | 6/160 | 0/26 | 6/186 | 17/187 |
| BronchitisInfections and infestations | 4/173 | 0/13 | 4/186 | 8/160 | 2/26 | 10/186 | 8/187 |
| Age, Categorical(Participants) | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 163 | 159 | 164 | 486 |
| >=65 years | 23 | 27 | 23 | 73 |
| Age, Continuous(years) | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg | Total |
|---|---|---|---|---|
| Mean | 52.6 ± 12.15 | 52.5 ± 12.46 | 49.8 ± 12.31 | 51.6 ± 12.36 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg | Total |
|---|---|---|---|---|
| Female | 156 | 157 | 154 | 467 |
| Male | 30 | 29 | 33 | 92 |
| Region of Enrollment(participants) | Adalimumab 40 mg | Sirukumab 50 mg | Sirukumab 100 mg | Total |
|---|---|---|---|---|
| Bulgaria | 1 | 1 | 0 | 2 |
| Chile | 5 | 2 | 3 | 10 |
| Colombia | 7 | 6 | 1 | 14 |
| Germany | 5 | 1 | 5 | 11 |
| Hungary | 0 | 1 | 2 | 3 |
| Lithuania | 12 | 15 | 9 | 36 |
| Mexico | 3 | 5 | 3 | 11 |
| Moldova | 2 | 6 | 4 | 12 |
| Poland | 21 | 17 | 20 | 58 |
| Romania | 4 | 5 | 4 | 13 |
| Russian Federation | 30 | 29 | 33 | 92 |
| Serbia | 20 | 19 | 26 | 65 |
| South Africa | 8 | 9 | 7 | 24 |
| Spain | 1 | 1 | 0 | 2 |
| Ukraine | 42 | 37 | 39 | 118 |
| United States | 25 | 32 | 31 | 88 |
Showing the first 100 of 109 sites across 16 countries. Choose a country and city above to see the rest.
Ran from Apr 2014 to primary completion in Aug 2016, 28 months.
Results were first posted in Sep 2017, 1 year after primary completion. A results delay was requested in Jul 2016.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 28 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Sirukumab
Janssen Research & Development, LLC →